IL11 and breast cancer: miR-204 orchestrates a complex interplay within the breast cancer TME by reducing infiltration of pro-tumorigenic myeloid cells while enhancing infiltration of anti-tumorigenic T cells, potentially limiting tumor invasion and enhancing immune surveillance; it also suppresses pro-tumorigenic IL-11 production, avoiding angiogenesis, tumor cell migration, and macrophage differentiation.